Novel Drug Delivery Systems
On this page
Direct answer
Novel drug delivery systems (NDDS) re-engineer the carrier, not the molecule, to deliver drug at the right place, rate and duration — fixing the peaks, troughs and wastage of conventional dosage forms. The family spans controlled-release matrix and membrane tablets that flatten the concentration-time curve; osmotic pumps that push drug through a laser-drilled orifice at a rate set by osmotic inflow, independent of gut pH and peristalsis; transdermal patches that cross intact skin for steady systemic input; and particulate carriers — microspheres, nanoparticles, liposomes and niosomes — that target drugs, cut toxicity or extend residence. The examinable distinction: a conventional tablet releases by disintegration and dissolution alone, while a delivery system adds a rate-controlling element (polymer matrix, membrane, osmotic engine or carrier) between drug and body, converting pharmacokinetics from patient-dependent to device-dependent.
What you must remember
- Controlled-release logic: conventional first-order release versus near zero-order; matrices (hydrophilic HPMC gel systems, insoluble wax matrices) and reservoir devices — dose dumping is the reservoir's risk and the matrix's safety advantage.
- Osmotic systems: semipermeable membrane, osmotic core, laser-drilled orifice; rate governed by water influx, largely unaffected by pH and motility.
- Transdermal prerequisites: potent, small (commonly under about 500 daltons) and lipophilic; components are drug reservoir or matrix, rate-controlling membrane, adhesive and release liner — scopolamine, nicotine, fentanyl and nitroglycerin patches are the classic four.
- Enhancement limits: penetration enhancers, iontophoresis and sonophoresis help, but intact skin still rejects macromolecules — why insulin has no patch.
- Particulate carriers: liposomes (phospholipid vesicles; liposomal amphotericin B the toxicity-reduction classic), niosomes (non-ionic surfactant vesicles, cheaper and stabler), PLGA microspheres and nanoparticles for sustained release.
- Targeting: passive tumour accumulation via leaky vasculature, ligand-decorated active targeting, and pH- or temperature-responsive release.
- Candidate properties for CR delivery: potency at low dose, small size, some solubility, wide therapeutic index — the standard short note.
One molecule, three delivery decisions
Consider a potent, short-half-life analgesic needing steady control. As a conventional tablet it demands six-hourly dosing on peak-trough cycles. Built into an HPMC hydrophilic matrix, the polymer hydrates to a gel layer through which drug diffuses while the matrix erodes, releasing nearly linearly for twelve hours — adherence doubles, but gut transit caps the technology. As an osmotic tablet, the drug sits in a core with an osmogent inside a semipermeable coat; water streams in and the saturated core pumps out through the single laser hole at machine-constant rate for up to a day, unfazed by pH, food or transit. As PLGA microspheres in a depot injection, release stretches over weeks as the polymer hydrolyses — the depot antipsychotic logic. Each trades a different constraint — matrix simplicity, osmotic cost, depot invasiveness — and each failure is distinct: matrix dose dumping if crushed, non-disintegrating shells as obstruction concerns in strictures, depot irreversibility once injected.
How the exam frames NDDS
Papers do not ask students to invent systems; they test whether the rate-controlling element can be named for each technology — polymer gel layer for the matrix, semipermeable membrane plus orifice for the osmotic pump, membrane or adhesive in the patch, the carrier itself for liposomes. The second angle is liposomes versus niosomes: same bilayer concept, but niosomes use non-ionic surfactants with cholesterol, cost less and store easily — a two-mark distinction with a fixed answer. Candidates also lose marks calling nanotechnology automatically "better"; examiners want the purpose of nanosizing — surface area, dissolution rate, reticuloendothelial uptake for targeting. A viva favourite asks why insulin has no transdermal patch: about 5800 daltons and hydrophilic, it fails every stratum corneum criterion, grounding the chapter in one molecule. Indian anchors: liposomal amphotericin B in visceral leishmaniasis care, and once-daily formulations as the commonest NDDS on any Indian shelf.
Frequently asked questions
What makes a delivery system "controlled release" rather than conventional?
It incorporates a rate-controlling element — matrix, membrane, osmotic mechanism or carrier — releasing drug at a predetermined, usually near zero-order rate instead of the immediate burst of disintegration and dissolution.
How does an elementary osmotic pump work?
Water enters an osmotically active core through a semipermeable membrane, building pressure that pumps drug out of a laser-drilled orifice at a rate independent of pH and gut motility.
Why do only certain drugs suit transdermal patches?
Skin admits only potent, lipophilic, low-molecular-weight molecules (commonly under about 500 daltons) at useful rates, so macromolecules and strongly hydrophilic drugs fail the stratum corneum.
Distinguish liposomes and niosomes.
Liposomes are phospholipid bilayer vesicles, while niosomes form from non-ionic surfactants with cholesterol — cheaper, more chemically stable and easier to store.
What is dose dumping and which design minimises it?
Abrupt release of the entire reservoir dose when rate control fails — a matrix disperses drug through the polymer, so breakage releases only a fragment, not a full reservoir.